Related Experiment Videos
Dexamethasone suppression test, schizophrenia and movement disorder.
A Aleem1, A Kulkarni, V K Yeragani
1Lafayette Clinic, Wayne State University School of Medicine, Detroit, Michigan.
Acta Psychiatrica Scandinavica
|December 1, 1988
Summary
The dexamethasone suppression test (DST) revealed higher scores for tardive dyskinesia (TD) and parkinsonism in schizophrenic patients who did not suppress. Post-dexamethasone cortisol levels correlated with movement disorder severity.
Area of Science:
- Neuroscience
- Psychiatry
- Endocrinology
Background:
- Schizophrenia is a complex psychiatric disorder.
- Tardive dyskinesia (TD) is a potential side effect of antipsychotic medication.
- The dexamethasone suppression test (DST) is used to assess hypothalamic-pituitary-adrenal (HPA) axis function.
Purpose of the Study:
- To investigate the relationship between HPA axis function, as measured by the DST, and the presence and severity of movement disorders in patients with schizophrenia.
Main Methods:
- Administered the dexamethasone suppression test (DST) to 20 patients diagnosed with schizophrenic illness.
- Assessed patients for tardive dyskinesia (TD) and parkinsonism using standardized scales.
- Measured post-dexamethasone cortisol levels.
Main Results:
- DST nonsuppressors showed significantly higher scores on TD and parkinsonism scales compared to suppressors.
- A significant positive correlation was observed between post-dexamethasone cortisol levels and the severity of movement disorders.
- These findings suggest a link between HPA axis dysregulation and motor symptoms in schizophrenia.
Conclusions:
- HPA axis dysregulation, indicated by DST nonsuppression, is associated with increased severity of movement disorders in schizophrenia patients.
- Cortisol levels after dexamethasone administration may serve as a biomarker for motor dysfunction in this population.
- Further research is warranted to explore the underlying mechanisms and potential therapeutic implications.